Squarepoint Ops LLC Takes Position in Replimune Group, Inc. $REPL

Key Points

• Squarepoint Ops LLC acquired 131,354 shares of Replimune Group during the second quarter, valued at approximately $1.45 million. Institutional investors and hedge funds collectively own 92.53% of the company.
• Analyst sentiment has improved, with several firms upgrading Replimune to positive ratings. The stock has a consensus rating of “Moderate Buy” and an average price target of $12.00.
• Replimune shares opened at $13.03, substantially above their 200-day moving average of $8.89, while the company reported a quarterly loss of $0.72 per share—slightly below analyst expectations.

Squarepoint Ops LLC purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 131,354 shares of the company's stock, valued at approximately $1,454,000. Squarepoint Ops LLC owned about 0.14% of Replimune Group as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REPL. Sterling Investment Advisors Ltd. purchased a new stake in Replimune Group in the 2nd quarter worth approximately $136,000. Readystate Asset Management LP boosted its holdings in Replimune Group by 116.6% during the second quarter. Readystate Asset Management LP now owns 299,958 shares of the company's stock worth $3,321,000 after buying an additional 161,470 shares in the last quarter. Syon Capital LLC purchased a new stake in Replimune Group during the second quarter worth $247,000. AXQ Capital LP grew its position in Replimune Group by 4.1% during the second quarter. AXQ Capital LP now owns 27,121 shares of the company's stock valued at $300,000 after buying an additional 1,056 shares during the period. Finally, Montanova Capital LLC increased its holdings in Replimune Group by 4.0% in the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company's stock valued at $48,595,000 after buying an additional 168,000 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Replimune Group

In other news, CEO Sushil Patel sold 39,341 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the completion of the sale, the chief executive officer directly owned 708,151 shares in the company, valued at $9,184,718.47. This represents a 5.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 9,256 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the transaction, the chief financial officer directly owned 215,852 shares in the company, valued at approximately $3,082,366.56. This represents a 4.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 79,124 shares of company stock worth $1,038,364 over the last three months. 5.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Wolfe Research raised shares of Replimune Group to an "outperform" rating in a research note on Tuesday, August 4th. Wedbush raised Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 target price for the company in a research note on Friday, August 7th. Piper Sandler upgraded Replimune Group from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 31st. JPMorgan Chase & Co. lifted their price target on shares of Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, August 26th. Finally, BMO Capital Markets raised shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.00.

Replimune Group Stock Performance

Shares of NASDAQ:REPL opened at $13.03 on Wednesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The business's 50 day moving average price is $12.59 and its 200-day moving average price is $8.89. The firm has a market capitalization of $1.22 billion, a PE ratio of -4.14 and a beta of 0.94. Replimune Group, Inc. has a 1 year low of $1.50 and a 1 year high of $16.33.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, equities research analysts expect that Replimune Group, Inc. will post -2.81 earnings per share for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company's approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.